Q4 2025 Kyntra Bio Inc Earnings Call Transcript
Key Points
- Kyntra Bio Inc (KYNB) completed the sale of FibroGen China to AstraZeneca, which extended their cash runway into 2028.
- The company initiated a Phase II trial for FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer, actively enrolling patients at multiple sites in the US.
- Kyntra Bio Inc (KYNB) received orphan drug designation for roxadustat in treating anemia associated with lower-risk myelodysplastic syndromes (MDS).
- The company reported promising interim results from the Phase Ib/II trial of FG-3246 in combination with enzalutamide, showing encouraging antitumor activity.
- Kyntra Bio Inc (KYNB) reduced its fixed cost infrastructure, maximizing its cash runway and enabling investment in US pipeline opportunities.
- Total revenue for the fourth quarter of 2025 was $1.3 million, a significant decrease from $3.1 million in the same period of 2024.
- The company recorded a net loss from continuing operations of $14.6 million for the fourth quarter of 2025, compared to a net loss of $8.7 million in the fourth quarter of 2024.
- R&D expenses increased to $7.3 million in the fourth quarter of 2025 from $6.9 million in the same period of 2024.
- Kyntra Bio Inc (KYNB) is still awaiting FDA feedback on the Phase III trial design for roxadustat, which has been delayed beyond the typical 30-day response period.
- The company faces challenges in commercializing its CD46 PET imaging agent, as it lacks the expertise of established players in the market.
Thank you for standing by, and welcome to Kyntra Bio's fourth quarter and full year 2025 earnings conference call. (Operator Instructions) I would now like to hand the call over to Gaia Shamis with LifeSci Advisors. Please go ahead.
Thank you, operator. Good afternoon, everyone. Thank you for joining today to discuss Kyntra Bio's fourth quarter and full year 2025 financial and business results. I'm Gaia Shamis from LifeSci Advisors.
Joining me on today's call are Thane Wettig, Chief Executive Officer; David DeLucia, Chief Financial Officer; and Carol Gaddum, Vice President of Product Development. Following the prepared remarks, we will open the call to your questions.
I would like to remind you that remarks made on today's call include forward-looking statements about Kyntra Bio.
Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas; financial guidance; the initiation, enrollment, design, conduct and results of clinical trials, regulatory
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
